Showing results (211-220 of 234) with videos related to

Sort By:
Pageof 24
Leukemia|June 1, 2022
Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trialTim H Brümmendorf, Jorge E Cortes, Dragana Milojkovic, et al.
Breast Cancer Research and Treatment|July 7, 2017
A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancerHope S Rugo, Olivier Trédan, Jungsil Ro, et al.
Blood|September 20, 2011
Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemiasFranck Emmanuel Nicolini, Grzegorz W Basak, Simona Soverini, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 15, 2020
First-in-Humans Trial of Dasatinib-Derivative Tracer for Tumor Kinase-Targeted PETSimone Krebs, Darren R Veach, Lukas M Carter, et al.
Journal of the National Cancer Institute|September 26, 2015
A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal CancerFrancesco Sclafani, Tae Y Kim, David Cunningham, et al.
Cell|August 12, 2008
Connecting microRNA genes to the core transcriptional regulatory circuitry of embryonic stem cellsAlexander Marson, Stuart S Levine, Megan F Cole, et al.
Biorxiv : the Preprint Server for Biology|June 12, 2025
Xist Repeat A coordinates an assembly of SR proteins to recruit SPEN and induce gene silencingJackson B Trotman, Alessandro Porrello, Scott A Schactler, et al.
Nature Reviews. Clinical Oncology|September 1, 2025
Apoptosis-targeting BH3 mimetics: transforming treatment for patients with acute myeloid leukaemiaAntonino Glaviano, Ellen Weisberg, Hiu Y Lam, et al.
Leukemia|April 9, 2025
Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1T315I treated with at least 2 prior TKIs: Phase 1 final resultsAndreas Hochhaus, Dong-Wook Kim, Jorge E Cortes, et al.
Leukemia|May 16, 2024
Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up resultsJorge E Cortes, Koji Sasaki, Dong-Wook Kim, et al.
Pageof 24